[Changing receptor status and treatment in breast cancer].
Sequential assays of estrogen receptors (ER) were done in 940 breast cancer in various stages of progression, and changes of ER were evaluated in relation to treatments and progression of cancer. The percentage of ER(+) cancers in primary breast cancer was shown to be 53.8% (333/619). In the preterminal stages, only 20% (6/30) of cancers were ER(+). During the disease-free interval, 37% (10/27) of ER(+) tumors changed to ER(-), and all ER(-) tumors remained negative. There was a most drastic change of ER(+) to ER(-) among patients with advanced breast cancer receiving adreno-oophorectomy or chemo-endocrine therapy. Appearent changes of ER during chemotherapy seem to be minimum.
D000970:Antineoplastic Agents / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000378:metabolism* / Q000628:therapy; D002369:Castration; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D011960:Receptors, Estrogen / Q000378:metabolism*; D013629:Tamoxifen / Q000008:administration & dosage
D000970:Antineoplastic Agents; D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D013629:Tamoxifen